Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
ZU
Zura Bio Limited Class A Ordinary Shares
ZURA
Mkt Cap
$373.3M
Volume
4.54M
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
ZU
ZURA
ZU
Zura Bio Limited Class A Ordinary Shares
ZURA
News
·
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering
Mkt Cap
$371.8M
Volume
4.54M
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering
JATT II Acquisition Corp, a blank check company focused on healthcare and biotechnology, successfully closed its $60 million IPO on April 20, 2026, offering 6 million shares at $10 per share on NASDAQ under ticker 'JATT'. The company, led by Dr. Someit Sidhu and sponsored by JATT Ventures II L.P., intends to pursue business combinations in healthcare and life sciences sectors with emphasis on data-driven therapeutic discovery approaches.
Benzinga · Apr 20, 2026
Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24+ Companies and 26+ Therapies | DelveInsight
A comprehensive analysis reveals a robust pipeline for hidradenitis suppurativa treatment, with 24+ companies developing 26+ therapies, focusing on innovative biologic and targeted approaches like IL-17 and JAK inhibitors to address significant unmet clinical needs.
GlobeNewswire Inc. · Oct 23, 2025
12 Health Care Stocks Moving In Monday's Intraday Session
Multiple health care and biotech stocks experienced significant price movements, with some stocks seeing substantial gains while others faced sharp declines during Monday's trading session.
Benzinga · Sep 29, 2025
Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know
The consensus price target hints at a 235.2% upside potential for Zura Bio Limited (ZURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research · May 31, 2024
How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%
The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Zura Bio Limited (ZURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research · May 15, 2024
Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should Know
Zura Bio Limited (ZURA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research · May 14, 2024
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
Upgrades According to RBC Capital, the prior rating for Montrose Environmental Group Inc (NYSE:MEG) was changed from Sector Perform to Outperform. In the second quarter, Montrose Environmental Gr showed an EPS of $0.13, compared to $0.03 from the year-ago quarter. At the moment, the stock has a 52-week-high of $55.00 and a 52-week-low of $26.64. Montrose Environmental Gr closed at $27.76 at the end of the last trading period. For Ameris Bancorp (NASDAQ:ABCB), DA Davidson upgraded the previous rating of Neutral to Buy. For the second quarter, Ameris had an EPS of $0.91, compared to year-ago quarter EPS of $1.18. The stock has a 52-week-high of $54.17 and a 52-week-low of $28.33. At the end of the last trading period, Ameris closed at $38.22. According to B of A Securities, the prior rating for Sabra Health Care REIT Inc (NASDAQ:SBRA) was changed from Neutral to Buy. For the second quarter, Sabra Health Care REIT had an EPS of $0.33, compared to year-ago quarter EPS of $0.39. At the moment, the stock has a 52-week-high of $14.32 and a 52-week-low of $10.08. Sabra Health Care REIT closed at $14.01 at the end of the last trading period. According to B of A Securities, the prior rating for Omega Healthcare Investors Inc (NYSE:OHI) was changed from Neutral to Buy. Omega Healthcare Invts earned $0.74 in the second quarter, compared to $0.76 in the year-ago quarter. The stock has a 52-week-high of $34.13 and a 52-week-low of $25.61. At the end of the last trading period, Omega Healthcare Invts closed at $33.64. B of A Securities upgraded the previous rating for Electronic Arts Inc (NASDAQ:EA) from Neutral to Buy. For the first quarter, Electronic Arts had an EPS of $1.14, compared to year-ago quarter EPS of $0.47. The current stock performance of Electronic Arts shows a 52-week-high of $140.30 and a 52-week-low of $108.53. Moreover, at the end of the last trading period, the closing price was at $124.59. Piper Sandler upgraded the previous rating for Exact Sciences Corp (NASDAQ:EXAS) from Neutral to Overweight. In the second quarter, Exact Sciences showed an EPS of $0.45, compared to $0.90 from the year-ago quarter. The stock has a 52-week-high of $100.77 and a 52-week-low of $29.29. At the end of the last trading period, Exact Sciences closed at $64.46. Jefferies upgraded the previous rating for Pinnacle Financial Partners Inc (NASDAQ:PNFP) from Underperform to Hold. In the second quarter, Pinnacle Finl Partners showed an EPS of $1.79, compared to $1.86 from the year-ago quarter. The stock has a 52-week-high of $89.00 and a 52-week-low of $43.31. At the end of the last trading period, Pinnacle Finl Partners closed at $66.25. For ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), JP Morgan upgraded the previous rating of Neutral to Overweight. In the second quarter, ACADIA Pharmaceuticals showed an EPS of $0.01, compared to $0.21 from the year-ago quarter. The current stock performance of ACADIA Pharmaceuticals shows a 52-week-high of $33.99 and a 52-week-low of $13.73. Moreover, at the end of the last trading period, the closing price was at $21.74. According to UBS, the prior rating for Rivian Automotive Inc (NASDAQ:RIVN) was changed from Neutral to Buy. In the second quarter, Rivian Automotive showed an EPS of $1.08, compared to $1.62 from the year-ago quarter. At the moment, the stock has a 52-week-high of $36.44 and a 52-week-low of $11.68. Rivian Automotive closed at $18.78 at the end of the last trading period. See all analyst ratings upgrades. Downgrades According to Barrington Research, the prior rating for StarTek Inc (NYSE:SRT) was changed from Outperform to Market Perform. For the second quarter, StarTek had an EPS of $0.04, compared to year-ago quarter EPS of $0.13. The current stock performance of StarTek shows a 52-week-high of $4.53 and a 52-week-low of $2.64. Moreover, at the end of the last trading period, the closing price was at $3.26. For Netstreit Corp (NYSE:NTST), B of A Securities downgraded the previous rating of Neutral to Underperform. In the second quarter, Netstreit showed an EPS of $0.30, compared to $0.28 from the year-ago quarter. The current stock performance of Netstreit shows a 52-week-high of $20.64 and a 52-week-low of $14.84. Moreover, at the end of the last trading period, the closing price was at $15.20. For Spirit Realty Capital Inc (NYSE:SRC), B of A Securities downgraded the previous rating of Neutral to Underperform. Spirit Realty Cap earned $0.91 in the second quarter, compared to $0.90 in the year-ago quarter. The stock has a 52-week-high of $44.65 and a 52-week-low of $32.48. At the end of the last trading period, Spirit Realty Cap closed at $33.59. For Realty Income Corp (NYSE:O), B of A Securities downgraded the previous rating of Buy to Neutral. For the second quarter, Realty Income had an EPS of $1.00, compared to year-ago quarter EPS of $0.97. The stock has a 52-week-high of $68.85 and a 52-week-low of $48.41. At the end of the last trading period, Realty Income closed at $50.55. According to Citigroup, the prior rating for ...Full story available on Benzinga.com
Benzinga · Oct 10, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2023
Upgrades For Hibbett Inc (NASDAQ:HIBB), Williams Trading upgraded the previous rating of Hold to Buy. Hibbett earned $0.85 in the second quarter, compared to $1.86 in the year-ago quarter. The current stock performance of Hibbett shows a 52-week-high of $75.38 and a 52-week-low of $34.86. Moreover, at the end of the last trading period, the closing price was at $36.86. According to Loop Capital, the prior rating for Netflix Inc (NASDAQ:NFLX) was changed from Hold to Buy. For the second quarter, Netflix had an EPS of $3.29, compared to year-ago quarter EPS of $3.20. The current stock performance of Netflix shows a 52-week-high of $485.00 and a 52-week-low of $211.81. Moreover, at the end of the last trading period, the closing price was at $406.93. For Cullen/Frost Bankers Inc (NYSE:CFR), UBS upgraded the previous rating of Sell to Neutral. In the second quarter, Cullen/Frost Bankers showed an EPS of $2.47, compared to $1.81 from the year-ago quarter. The stock has a 52-week-high of $160.31 and a 52-week-low of $92.55. At the end of the last trading period, Cullen/Frost Bankers closed at $95.16. For Abercrombie & Fitch Co (NYSE:ANF), Morgan Stanley upgraded the previous rating of Underweight to Equal-Weight. In the second quarter, Abercrombie & Fitch showed an EPS of $1.10, compared to $0.30 from the year-ago quarter. The current stock performance of Abercrombie & Fitch shows a 52-week-high of $53.02 and a 52-week-low of $14.06. Moreover, at the end of the last trading period, the closing price was at $50.46. Cantor Fitzgerald upgraded the previous rating for Ardelyx Inc (NASDAQ:ARDX) from Neutral to Overweight. Ardelyx earned $0.08 in the second quarter, compared to $0.19 in the year-ago quarter. At the moment, the stock has a 52-week-high of $5.12 and a 52-week-low of $0.82. Ardelyx closed at $3.51 at the end of the last trading period. For Shift4 Payments Inc (NYSE:FOUR), Morgan Stanley upgraded the previous rating of Underweight to Equal-Weight. In the second quarter, Shift4 Payments showed an EPS of $0.74, compared to $0.33 from the year-ago quarter. The current stock performance of Shift4 Payments shows a 52-week-high of $76.40 and a 52-week-low of $36.37. Moreover, at the end of the last trading period, the closing price was at $54.72. For Avista Corp (NYSE:AVA), Keybanc upgraded the previous rating of Underweight to Sector Weight. In the second quarter, Avista showed an EPS of $0.23, compared to $0.16 from the year-ago quarter. The current stock performance of Avista shows a 52-week-high of $45.28 and a 52-week-low of $32.27. Moreover, at the end of the last trading ...Full story available on Benzinga.com
Benzinga · Aug 25, 2023
Where Zura Bio Stands With Analysts
Analysts have provided the following ratings for Zura Bio (NASDAQ:ZURA) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 0 0 0 These 4 analysts have an average price target of $19.0 versus the current price of Zura Bio at $6.8772, implying upside. Below is a summary of how these 4 analysts rated Zura Bio over the past 3 months. ...Full story available on Benzinga.com
Benzinga · Aug 15, 2023
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session. BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares dropped 62.2% to $6.68 after the company released topline results from TRANQUILITY II Phase 3 trial of BXCL501 for acute treatment of Alzheimer's Disease-related agitation. Liquidia Corporation (NASDAQ: LQDA) fell 15% to $8.42. Liquidia said it is evaluating claim of ...
Benzinga · Jun 29, 2023
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
ZU
ZURA
Zura Bio Limited Class A Ordinary Shares
Buy
Sell
Market
Limit
Soon
ZURA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ZURA yet.
Related Tickers
Earnings